In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on January 22, 2026, RBC Capital upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sector Perform to Outperform. Analyst Price Forecast Suggests 8.58% Upside ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best future stocks to buy for the long term. On January 12, Bernstein analyst William Pickering upgraded Vertex Pharmaceuticals to ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Last year, Vortex advanced the technical understanding of the Robinsons River Salt Project (“Robinsons Project”) in Newfoundland & Labrador, Canada, through a focused collaboration with the University ...